As of 2025-10-22, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.2x - 8.9x | 6.3x |
| Forward P/E multiples | 7.8x - 12.8x | 9.9x |
| Fair Price | (15.85) - (17.64) | (16.39) |
| Upside | -534.4% - -583.4% | -549.0% |
| Date | EV/EBITDA |